Kadimastem’s Stem Cell Therapy Holds Promise For Treating ALS

The Israeli biotechnology company Kadimastem has announced exciting results from their first preclinical study in ALS. The company’s proprietary technology is based on stem cell-derived astrocyte precursor cells, which are transplanted into the cerebrospinal fluid (CSF) to provide support for degenerating motor neurons. The technology was initially developed out of the laboratory of Professor Michel Revel, Kadimastem’s Chief Scientist and also the lead inventor of the blockbuster multiple sclerosis drug Rebif®. Kadimastem’s preclinical study in ALS demonstrated that the transplanted cells increase survival and motor function in an ALS mouse model. Next steps are to engage the FDA and other regulatory authorities in discussions in preparation for a human clinical trial. Keep your finger on the pulse of this company!

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail